Design Therapeutics experienced a significant increase in net loss for the first quarter of 2025, primarily driven by higher research and development expenses related to clinical trials and early-stage research programs. The company maintains a strong cash and investment securities balance, which is anticipated to fund operations for more than the next 12 months.

Design Therapeutics reported a net loss of $13.7 million for Q4 2024, with R&D expenses at $12.2 million and G&A expenses at $4.5 million. The company is well-capitalized with $245.5 million in cash and securities, expected to fund operations into 2029.

Design Therapeutics reported a net loss of $13.0 million for the third quarter of 2024. The company's cash, cash equivalents, and marketable securities totaled $254.1 million as of September 30, 2024, expected to fund operations into 2029. Phase 1 trial in FECD initiated with data expected in the first half of 2025.

Design Therapeutics announced its second quarter 2024 financial results, highlighting the advancement of its GeneTAC™ candidates. The company is on track to start patient trials for DT-216P2 in 2025 and initiate Phase 1 development for DT-168 in 2024. With a cash position of $261.0 million, Design Therapeutics expects to fund its planned operating expenses into 2029.

Design Therapeutics reported a net loss of $11.1 million for the first quarter of 2024. The company's cash and securities totaled $270.7 million, expected to fund operations into 2029. Key programs in FA, FECD, HD, and DM1 are advancing, with potential for clinical proof-of-concept.

Design Therapeutics reported a net loss of $11.8 million for the fourth quarter of 2023. The company's cash and securities totaled $281.8 million at year-end, supporting a five-year operating runway. Progress was highlighted across the GeneTAC™ platform, including a new drug product for Friedreich Ataxia and IND clearance for Fuchs Endothelial Corneal Dystrophy.

Design Therapeutics reported a net loss of $15.8 million for Q3 2023. The company is focusing on long-term growth, capital resource allocation, and cost savings, with current cash and securities expected to fund operations through 2028. A comprehensive portfolio update is planned for early 2024.

Design Therapeutics reported initial data from Phase 1 multiple-ascending dose trial of DT-216 for Friedreich Ataxia showed significant increase in FXN mRNA Levels in Skeletal Muscle. The company had $303.1 million in cash and securities, expected to support operating runway through 2026.

Design Therapeutics reported its first quarter 2023 financial results, highlighting progress in its GeneTAC™ small molecule pipeline. Initial data from the Phase 1 multiple-ascending dose trial of DT-216 for Friedreich Ataxia is expected in the third quarter of 2023. The company's cash and securities are expected to support operating runway through 2025.

Design Therapeutics reported its Q4 and full year 2022 financial results, highlighting the progress of its GeneTAC™ small molecules pipeline. The company's lead candidate, DT-216, showed promising initial results in a Phase 1 clinical trial for Friedreich ataxia, and the company is advancing its programs in FECD and DM1 towards clinical development.

Design Therapeutics reported its Q3 2022 financial results, highlighting the progress of its Phase 1 clinical program for DT-216, which is on track for initial data reporting in December 2022, and the initiation of dosing in the multiple-ascending dose trial. The company's financial position remains strong with $344.2 million in cash and securities.

Design Therapeutics reported a net loss of $15.0 million for the second quarter of 2022 and holds a strong financial position with $359.4 million in cash and securities. The company is advancing its pipeline, with initial data from the Friedreich Ataxia Phase 1 trial expected in the fourth quarter of 2022.

Design Therapeutics reported its Q1 2022 financial results, highlighting the initiation of a Phase 1 trial for DT-216 in Friedreich Ataxia and promising preclinical data for Fuchs Endothelial Corneal Dystrophy. The company's cash position stands strong at $371.2 million.

Design Therapeutics reported its Q4 and full year 2021 financial results, highlighting the clearance of the IND for DT-216 and progress in developing GeneTACTM molecules for myotonic dystrophy type-1 and Fuchs endothelial corneal dystrophy. The company ended the year well-capitalized with $384.1 million in cash and investments.

Design Therapeutics reported a net loss of $11.3 million for the third quarter ended September 30, 2021. The company's lead GeneTACTM program for Friedreich Ataxia is on track for clinical initiation in the first half of 2022.

Design Therapeutics reported a net loss of $7.6 million for the second quarter of 2021. The company's research and development expenses were $5.0 million, and general and administrative expenses were $2.7 million. As of June 30, 2021, the company had cash, cash equivalents and investment securities of $402.8 million.

Design Therapeutics reported a net loss of $5.5 million for the first quarter ended March 31, 2021. The company successfully completed a $276 million IPO and is on track to initiate a Phase 1 clinical trial for Friedreich Ataxia in the first half of 2022.